×
Entrez Id:
2214
Gene Symbol:
FCGR3A
FCGR3A
0.030
Biomarker
disease
BEFREE
Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor FcγRIIIa 158(V/F) polymorphism.
20730791
2010
×
Entrez Id:
2214
Gene Symbol:
FCGR3A
FCGR3A
0.030
GeneticVariation
disease
BEFREE
The FCGR3A -158V/V genotype was associated with LON compared with V/F (P = 0.028) and F/F genotypes (P = 0.005).
21883784
2012
×
Entrez Id:
1649
Gene Symbol:
DDIT3
DDIT3
0.010
Biomarker
disease
BEFREE
Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP -R for diffuse large B-cell lymphoma.
21883784
2012
×
Entrez Id:
712
Gene Symbol:
C1QA
C1QA
0.010
GeneticVariation
disease
BEFREE
The FCGR3A-V158F but not the C1qA -A276G polymorphism influenced the risk of developing LON .
21883784
2012
×
Entrez Id:
2214
Gene Symbol:
FCGR3A
FCGR3A
0.030
Biomarker
disease
BEFREE
FCGR3A 158V/V and presentation with LON were associated with a longer flare-free survival (p = 0.023 and p = 0.031, respectively).
28270182
2017
TNFSF13B
0.020
GeneticVariation
disease
BEFREE
In this study, we aimed to investigate the role of established Fcγ receptor gene (FCGR) polymorphisms and B-cell-activating factor (BAFF ) gene promoter polymorphisms for the development of LON and for the efficacy of rituximab in patients with rheumatic diseases.
28270182
2017
TNFSF13B
0.020
AlteredExpression
disease
BEFREE
BAFF levels increased from baseline (median: 0.62 ng/ml) to the post-treatment evaluation (median: 1.16 ng/ml; p < 0.001); post-treatment levels were higher in the LON group ( p = 0.021).
29783918
2018
×
Entrez Id:
10541
Gene Symbol:
ANP32B
ANP32B
0.010
Biomarker
disease
BEFREE
Distinct roles of BAFF and APRIL are implicated: BAFF may contribute to LON development, whereas high APRIL levels may be predictive.
29783918
2018
×
Entrez Id:
3569
Gene Symbol:
IL6
IL6
0.010
AlteredExpression
disease
BEFREE
IL-6 and GM-CSF levels decreased in the non-LON group ( p < 0.001), but not in LON patients.
29783918
2018
×
Entrez Id:
1437
Gene Symbol:
CSF2
CSF2
0.010
AlteredExpression
disease
BEFREE
IL-6 and GM-CSF levels decreased in the non-LON group ( p < 0.001), but not in LON patients.
29783918
2018
×
Entrez Id:
8741
Gene Symbol:
TNFSF13
TNFSF13
0.010
Biomarker
disease
BEFREE
Distinct roles of BAFF and APRIL are implicated: BAFF may contribute to LON development, whereas high APRIL levels may be predictive.
29783918
2018
×
Entrez Id:
1440
Gene Symbol:
CSF3
CSF3
0.010
Biomarker
disease
BEFREE
Late-onset neutropenia (LON ) requiring granulocyte colony-stimulating factor occurred more frequently in the ABOi group than in the ABOc group (4 vs. 0 patients) (P < 0.001).
31673829
2020